A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell.

The year 2015 marked the inception of Sanyou Bio's technological journey, laying the foundation for its core technology platform. The R&D team devoted itself to the development of display vectors, ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling mechanism ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

A newly developed vaccine against a group of viruses including SARS-CoV-2 is producing promising results in mice, part of the ...

Scientists at the University of Pittsburgh have tested a broadly neutralizing antibody (bnAb) that binds the stem of a protein against H5N1 avian influenza, which prevented severe disease in nonhuman ...

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

A study published in Science examines the application of the broadly neutralizing antibody (bnAb) MEDI8852* as a pre-exposure prophylaxis in cynomolgus macaques, with the objective of evaluating its ...

New research from the Florida State University Department of Chemistry and Biochemistry shows that a particular type of monoclonal antibody known as NISTmAb retains its structure even if the sugar ...